Guizhou Xinbang Pharmaceutical Co., Ltd.

SZSE:002390 Stock Report

Market Cap: CN¥5.6b

Guizhou Xinbang Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Guizhou Xinbang Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth19.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings

Jun 26
Investors Aren't Buying Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Earnings

These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely

May 24
These 4 Measures Indicate That Guizhou Xinbang Pharmaceutical (SZSE:002390) Is Using Debt Safely

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Guizhou Xinbang Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:002390 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20246,251246648791N/A
3/31/20246,438293642791N/A
12/31/20236,461287655791N/A
9/30/20236,487230663787N/A
6/30/20236,463249208322N/A
3/31/20236,377204322457N/A
1/1/20236,350224432591N/A
9/30/20226,435304512704N/A
6/30/20226,517252465698N/A
3/31/20226,590274265530N/A
1/1/20226,472273204458N/A
9/30/20216,289260286512N/A
6/30/20216,241290362552N/A
3/31/20216,060259428588N/A
12/31/20205,846174604742N/A
9/30/20205,916159639829N/A
6/30/20206,080151783988N/A
3/31/20206,339161793996N/A
12/31/20196,655236679886N/A
9/30/20196,573-1,360574743N/A
6/30/20196,584-1,371247464N/A
3/31/20196,630-1,308-243-16N/A
12/31/20186,580-1,297-482-219N/A
9/30/20186,651337-587-298N/A
6/30/20186,527368-521-176N/A
3/31/20186,160341N/A127N/A
12/31/20176,002319N/A202N/A
9/30/20175,800293N/A187N/A
6/30/20175,437263N/A-68N/A
3/31/20175,350255N/A-236N/A
12/31/20165,157246N/A-199N/A
9/30/20165,044243N/A-149N/A
6/30/20164,864223N/A138N/A
3/31/20164,488185N/A294N/A
12/31/20154,180174N/A217N/A
9/30/20153,788189N/A86N/A
6/30/20153,477180N/A-263N/A
3/31/20153,217172N/A-225N/A
12/31/20142,476145N/A-199N/A
9/30/20141,732100N/A-171N/A
6/30/20141,11369N/A-18N/A
3/31/201457239N/A-42N/A
12/31/201356940N/A-21N/A
9/30/201352942N/A-45N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 002390's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if 002390's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 002390's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 002390's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 002390's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 002390's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y